Reader sentiment, not investment advice. One vote per visitor; click again to change it.
ADRX last changed hands at $19.05 (up 4.38%). At $1.95B, Adarx Pharmaceuticals is ranked #2804 by size among the 3132 stocks on BeStock.
The 52-week range is $17.30 to $23.21. Today's price is about 30% of the way from the low to the high.
For the quarter ended Jun 2026 it reported $746,000.00 in revenue, up 258.7% from a year earlier, and a net loss of $25.76M.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3131 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ADRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Morningstar’s fair value model puts the stock at $28.79, so shares trade 33.8% below that estimate. On earnings multiple, it sits in the 55th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
Quote as of Oct 6, 2026 6:00 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$19.05 is the latest print for ADRX, a move of +4.38% against yesterday's close of $18.25. Today's low and high so far: $17.30 and $19.40.
Equity value comes to $1.95B at the current price. By that measure it is number 2804 of the 3132 names in our coverage.
The year's floor is $17.30 and the ceiling $23.21. Shares are 17.9% away from that ceiling.
Our data shows no dividend paid by Adarx Pharmaceuticals over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ADRX.